Introduction: From March 2016, patients with M+ NET are treated with PRRT at the Netherlands Cancer Institute.
Aim(s): The goal of this study was to evaluate adverse events and symptomatic change in our patient population.
Materials and methods: Patients with irresectable or metastatic progressive disease, positive lesions on 68Ga-DOTATATE PET/CT, adequate renal function and bone marrow capacity were accepted for PRRT (four cycles of 3.7-7.8 GBq, 10 weeks interval). The administered activity was adjusted based on clinical and hematological analysis. Hematological assessments were performed prior to therapy and 3, 6, and 8.5 weeks after each cycle. Adverse events (CTCTAE v4.03) and NET symptoms are evaluated by a nuclear medicine physician before therapy and 6 weeks after each cycle.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MSc Daphne Huizing
To read results and conclusion, please login ...
Further abstracts you may be interested in